Roche creates organoid research institute to shake up drug discovery and development
BIOMARKER
Gray Frame Corner
Gray Frame Corner
1. Roche believes preclinical drug development is on the verge of a major change.
Gray Frame Corner
Gray Frame Corner
2. The company has set up the Institute of Human Biology (IHB) to create better models for drug development.
Gray Frame Corner
Gray Frame Corner
3. Current drug developers rely on animal models, which often translate poorly into humans.
Gray Frame Corner
Gray Frame Corner
4. Roche sees human model systems, like organoids, as a more accurate predictor of patient response to drugs.
Gray Frame Corner
Gray Frame Corner
5. IHB aims to combine biology, bioengineering, and data science around human model systems for drug discovery.
Gray Frame Corner
Gray Frame Corner
6. Roche plans to grow IHB to around 250 scientists and bioengineers over the next four years.
Gray Frame Corner
Gray Frame Corner
7. The IHB will collaborate with ETH Zurich and EPFL, the two Swiss Federal Institutes of Technology.
Gray Frame Corner
Gray Frame Corner
8. IHB was launched a year after Roche hired organoids research pioneer Hans Clevers as head of pharma research and early development.
Gray Frame Corner
Gray Frame Corner
9. Clevers believes human organoids can be implemented at every step of drug development, from target identification to personalized medicine.
Gray Frame Corner
Gray Frame Corner
10. Roche's IHB is an example of the company's smart, foundational investments in research and development.
Gray Frame Corner
Gray Frame Corner
Swipe up for more BIOMARKER news!
Learn more